Streetwise Articles By Production Types

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial

Streetwise Reports (04/11/2022)

Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%.

Tags: Biotechnology / Pharmaceuticals

Co. Uses Protein Modulation to Treat Cancer

Streetwise Reports (04/09/2022)

Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend.

Tags: Biotechnology / Pharmaceuticals

FDA Approves Bipolar and Schizophrenia Drug

Streetwise Reports (04/06/2022)

BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMI™ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Tags: Biotechnology / Pharmaceuticals

Can We Make a Pill to End the Pandemic?

Contributed Opinion

Vision and Value (04/04/2022)

Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial

Streetwise Reports (04/02/2022)

NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors.

Tags: Biotechnology / Pharmaceuticals

Chen's Top Picks for Q2 2022

Streetwise Reports (04/01/2022)

Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks.

Tags: GoldBiotechnology / PharmaceuticalsOil & Gas - Exploration & Production

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial

Streetwise Reports (03/31/2022)

Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer.

Tags: Biotechnology / Pharmaceuticals

Biotech Firm's Shares Double on $6B Deal

Streetwise Reports (03/29/2022)

Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial

Streetwise Reports (03/23/2022)

Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Gets $2M Grant for Parkinson's Treatment

Streetwise Reports (03/22/2022)

Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease.

Tags: Biotechnology / Pharmaceuticals

Co. Awaits FDA Approval of Drug, Prepares for Launch

Research Report

(03/21/2022)

The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

Drug Co. Gets PDUFA Date for TKI

Research Report

(03/20/2022)

"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug

Streetwise Reports (03/19/2022)

Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder.

Tags: Biotechnology / Pharmaceuticals

Catalyst Could Push Pharma to Break Out

Contributed Opinion

Michael Sheikh (03/18/2022)

This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Enjoys Gains From Kidney Cancer Drug

Streetwise Reports (03/14/2022)

Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC).

Tags: Biotechnology / Pharmaceuticals

License Revenues Kick in for Biopharma Co.

Streetwise Reports (03/12/2022)

Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner.

Tags: Biotechnology / Pharmaceuticals

Biotech Firm Should Increase Sales by 20% This Year

Research Report

(03/10/2022)

This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings

Research Report

(03/10/2022)

An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval

Streetwise Reports (03/09/2022)

Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma.

Tags: Biotechnology / Pharmaceuticals

This Year Should Be Catalyst Rich for Oncology Pharma Co.

Research Report

(03/01/2022)

An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Biotech to Take Novel Cancer Drug to Market in H1/22

Streetwise Reports (02/28/2022)

This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Posts 364% YOY Revenue Increase in Q421

Streetwise Reports (02/25/2022)

Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer.

Tags: Biotechnology / Pharmaceuticals

Super Computers Create Powerful Drugs for Alzheimer's

Streetwise Reports (02/25/2022)

A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Decreases BMI by 14.3% in Obesity Trial

Streetwise Reports (02/18/2022)

Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS).

Tags: Biotechnology / Pharmaceuticals

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences

(02/14/2022)

Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share.

Tags: Biotechnology / Pharmaceuticals

The Life Sciences Report

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial

Co. Uses Protein Modulation to Treat Cancer

FDA Approves Bipolar and Schizophrenia Drug

Can We Make a Pill to End the Pandemic?

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial

Chen's Top Picks for Q2 2022

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial

Biotech Firm's Shares Double on $6B Deal

Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial

Biotech Co. Gets $2M Grant for Parkinson's Treatment

Co. Awaits FDA Approval of Drug, Prepares for Launch

Drug Co. Gets PDUFA Date for TKI

Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug

Catalyst Could Push Pharma to Break Out

Biopharma Co. Enjoys Gains From Kidney Cancer Drug

License Revenues Kick in for Biopharma Co.

Biotech Firm Should Increase Sales by 20% This Year

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings

Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval

This Year Should Be Catalyst Rich for Oncology Pharma Co.

Biotech to Take Novel Cancer Drug to Market in H1/22

Pharma Co. Posts 364% YOY Revenue Increase in Q421

Super Computers Create Powerful Drugs for Alzheimer's

Pharma Co. Decreases BMI by 14.3% in Obesity Trial

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

More Experts